USPTO Allows Accelerated Path For COVID-19 Products Across Medical, Health Care Sectors
Executive Summary
USPTO pilot program aims to examine applications for COVID-19 products subject to approval by FDA within 6 to 12 months. Prioritized examination is available solely for small entities and would save them $2,000.